Video Q&A: Cynosure President and CEO Michael Davin Print
By Staff and Wire Reports   
Thursday, 12 July 2012 00:00
In an exclusive video interview with healthcare analyst David Moskowitz, Cynosure (NASDAQ:CYNO) President and CEO Michael Davin discusses Cynosure`s expanding position in the global market as a provider of light-based medical treatments and the strategic shifts that allowed Cynosure to weather the last few years of worldwide economic recession.

Even as competitors fell apart, says Davin, Cynosure continued to innovate: "We spent at the same level [on R&D] as we did during the high times [...] we have $77 million in cash, no debt, and last year we acquired two companies and also acquired a distribution relationship." He explains how the company made major cuts to operating expenses in 2009 and 2010, resulting in top-line revenue growth of 35% in 2011 - more than any other company in their industry, including public names like Syneron Medical (NASDAQ:  ELOS), Palomar Medical (PMTI), Solta Medical (SLTM) or Cutera (CUTR).

Cynosure develops and manufactures broad array of light-based aesthetic and medical treatment systems. Its products are used to provide a diverse range of treatment applications such as hair removal, skin rejuvenation and scar reduction, as well as the treatment of vascular lesions.

Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. The company's productfolio includes AcclaimT, AccoladeT, AffirmT, Affinity QST, ApogeeT, CynergyT, EliteT, SmartlipoT, Smartlipo MPXT, TriActiveT, etc. Its EliteT Aesthetic Workstation is the most comprehensive laser hair removal system, and TriActiveT Cellulite Workstation is the only over-the-counter laser cleared for laser cellulite treatment and temporary cellulite reduction.

Cynosure has collaboration agreements with CoolTouch, Inc., Unilever Plc, BioChemics, Inc., Depilite Medic Spa, American Laser Centers, Palomar Medical Technologies Inc, and DUSA Pharmaceuticals Inc, and others.

Watch the video:


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus